Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ventavia Research Group

Neither a doctor nor a teaching hospital

Research payments

$473,995

230 payments

Through program year 2025, Ventavia Research Group is reported as receiving $473,995 in research payments, across 230 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $94,128 149
2024 Research $42,152 3
2023 Research $1,420 2
2022 Research $66,629 12
2021 Research $14,219 19
2020 Research $146,652 33
2019 Research $108,794 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Seqirus USA Inc $266,095 42 payments
  2. Boehringer Ingelheim International GmbH $113,082 145 payments
  3. Eli Lilly and Company $67,759 6 payments
  4. Boehringer Ingelheim Pharma GmbH & Co.KG $23,199 7 payments
  5. Alnylam Pharmaceuticals Inc. $1,688 24 payments
  6. Pfizer Inc. $1,172 5 payments
  7. Lundbeck LLC $1,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects $159,403 35 payments
  2. A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine QIVc and a United States Licensed Quadrivalent Influenza Virus Vaccine QIV in Healthy Subjects 6 Months Through 47 Months $106,692 7 payments
  3. EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $94,128 149 payments
  4. A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine $66,339 4 payments
  5. BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) $42,152 3 payments
  6. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) $1,688 24 payments
  7. A Phase 4 Randomized Double-Blind Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine $1,420 2 payments
  8. An Open Label Trial of ALD403 Eptinezumab in Chronic Migraine PREVAIL $1,000 1 payment
  9. A Phase 3 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Adults 65 Years of Age With Prior Pneumococcal Vaccination $601 2 payments
  10. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccinenaive Adults 18 Years of Age and Older $501 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record